Comprehensive NGS Profiling to Enable Detection of ALK Gene Rearrangements and MET Amplifications in Non-Small Cell Lung Cancer
We evaluate the analytical performance of the PGDx™ elio™ tissue complete assay, a 505 gene next-generation sequencing (NGS) tissue-based assay, that has now been FDA-cleared for use by physicians to help guide treatment decisions for cancer patients, using a NSCLC cohort of 38 patients.
- Type: Cancer Genomics
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000000016 | NextSeq 500 | 38 |
| Publications | Citations |
|---|---|
|
Comprehensive NGS profiling to enable detection of <i>ALK</i> gene rearrangements and <i>MET</i> amplifications in non-small cell lung cancer.
Front Oncol 13: 2023 1225646 |
0 |